<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rb1 plays an important role in cell cycle progression and therefore may be involved in <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> of colonic cells </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of our research was to define the potential role of Rb1 as a prognostic biomarker in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and to examine the role of miR-106a in Rb1 regulation as it functionally binds to 3'UTR of transcribed <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We examined LOH and promoter methylation status </plain></SENT>
<SENT sid="3" pm="."><plain>Real-time PCR was used for Rb1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and miR-106a, and immunohistochemistry for protein expression analysis </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the results obtained from patients' samples were correlated with the clinicopathological parameters in order to determine its influence on the <z:hpo ids='HP_0003745'>sporadic</z:hpo> colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>LOH showed no correlation with <z:chebi fb="2" ids="33699">mRNA</z:chebi> and pRb expression </plain></SENT>
<SENT sid="6" pm="."><plain>51.5% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples were scored negative for pRb staining </plain></SENT>
<SENT sid="7" pm="."><plain>Despite this finding, we detected overexpression of Rb1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples in comparison to the adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissue (p=0.023) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="2" ids="33699">mRNA</z:chebi> overexpression was consistent with Rb1 promoter methylation analysis results, which showed no methylation in the investigated samples </plain></SENT>
<SENT sid="9" pm="."><plain>Expression analysis of miR-106a in the patients samples showed its overexpression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (p&lt;10(-4)) </plain></SENT>
<SENT sid="10" pm="."><plain>Negative pRb score was expected according to the definition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes and their proposed role in the <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> of the cells </plain></SENT>
<SENT sid="11" pm="."><plain>The observed discrepancy between <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression can be explained by a regulatory mechanism that inhibits translation, such as microRNA silencing </plain></SENT>
<SENT sid="12" pm="."><plain>Our results suggest that miR-106a might have a regulatory role for Rb1 in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>